MDWD
MediWound Ltd.
$17.04
-$0.82(-4.59%)
43
Overall
--
Value
50
Tech
36
Quality
Market Cap
$205.68M
Volume
177.91K
52W Range
$14.14 - $22.51
Target Price
$30.67
Company Overview
| Mkt Cap | $205.68M | Price | $17.04 |
| Volume | 177.91K | Change | -4.59% |
| P/E Ratio | -6.8 | Open | $17.50 |
| Revenue | $20.0M | Prev Close | $17.86 |
| Net Income | $-30.2M | 52W Range | $14.14 - $22.51 |
| Div Yield | N/A | Target | $30.67 |
| Overall | 43 | Value | -- |
| Quality | 36 | Technical | 50 |
No chart data available
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
MediWound’s Q3 2025: Growth and Strategic Advances
TipRanks Auto-Generated Newsdesk•2 hours ago
Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Exact Sciences (EXAS)
Howard Kim•15 hours ago
MediWound’s EscharEx Study: A Potential Game-Changer for Venous Leg Ulcers
TipRanks Clinical-Trials-Auto-Generated Newsdesk•24 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDWD | $17.04 | -4.6% | 177.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |